Table 1:
Baseline Characteristics of the study population by quartile of sCD14
| Characteristic* | Total (n=5217) | Quartile 1 (n=1305) | Quartile 2 (n=1304) | Quartile 3 (n=1304) | Quartile 4 (n=1304) | P Value |
|---|---|---|---|---|---|---|
| sCD14, ng/ml | 1636±357 | 1244±134 | 1498±56 | 1703±64 | 2098±307 | |
| Age, years | 72.7±5.5 | 72.2±5.3 | 72.3±5.31 | 72.8±5.5 | 73.6±6.0 | <0.001 |
| Male, n (%) | 2200 (42.2) | 692 (53) | 615 (47.2) | 477 (36.6) | 416 (31.9) | <0.001 |
| Black race, n (%) | 771 (14.8) | 327 (25.1) | 175 (13.4) | 146 (11.2) | 123 (9.4) | <0.001 |
| Education ≥12th grade, n (%) | 2286 (43.9) | 630 (48.5) | 577 (44.4) | 560 (43) | 519 (40) | <0.001 |
| BMI, kg/m2 | 26.6±4.7 | 27.1±4.6 | 26.8±4.5 | 26.6±4.7 | 26.0±4.7 | <0.001 |
| Current smoking, n (%) | 636 (12.2) | 129 (9.9) | 138 (10.6) | 173 (13.3) | 196 (15) | <0.001 |
| Heavy alcohol use, n (%) | 554 (10.7) | 108 (8.3) | 145 (11.2) | 157 (12.1) | 144 (11.1) | 0.011 |
| Physical activity score, n (%) | <0.001 | |||||
| 0 | 1205 (23.5) | 256 (19.9) | 265 (20.6) | 297 (23.2) | 387 (30.3) | |
| 1 | 2689 (2.4) | 688 (53.5) | 691 (53.7) | 657 (51.3) | 653 (51.1) | |
| 2 | 237 (24.1) | 343 (26.7) | 331 (25.7) | 326 (25.5) | 237 (18.6) | |
| Systolic blood pressure, mmHg | 137±22 | 135±21 | 137±21 | 137±22 | 138±22 | 0.001 |
| Antihypertensive medication, n (%) | 2374 (46) | 534 (41) | 571(44) | 607 (47) | 662 (51) | <0.001 |
| Diabetes, n (%) | 805 (15.5) | 166 (12.8) | 197 (15.1) | 188 (14.5) | 254 (19.5) | <0.001 |
| Estrogen, n (%) | 371 (12.3) | 140 (22.9) | 88 (12.8) | 83 (10) | 60 (6.8) | <0.001 |
| Prevalent CHD, n (%) | 896 (17.2) | 219 (16.8) | 224 (17.2) | 212 (16.3) | 241 (18.5) | 0.479 |
| Prevalent atrial fibrillation, n (%) | 128 (2.5) | 35 (2.7) | 30 (2.3) | 40 (3.1) | 23 (1.8) | 0.168 |
| Prevalent stroke, n (%) | 197 (3.8) | 33 (2.5) | 44 (3.4) | 44 (3.4) | 76 (5.8) | <0.001 |
| Prevalent TIA, n (%) | 128 (2.5) | 23 (1.8) | 34 (2.6) | 31 (2.4) | 40 (3.1) | 0.186 |
| Frailty score, n (%) | <0.001 | |||||
| 0 | 2265 (47.8) | 596 (49.1) | 604 (50.3) | 593 (50.3) | 472 (41.4) | |
| 1 | 2182 (46.1) | 556 (45.8) | 542 (45.1) | 531 (45.0) | 553 (48.5) | |
| 2 | 287 (6.1) | 61 (5.0) | 55 (4.6) | 55 (4.7) | 116 (10.2) | |
| LDL, mg/dl | 130 ±36 | 126±33 | 130 ±33 | 132 ±36 | 133 ±39 | <0.001 |
| HDL, mg/dl | 54 ±16 | 54±16 | 54±16 | 55±15 | 55±16 | 0.534 |
| eGFR, ml/min/1.73 m2 | 78±20 | 85±18 | 82±18 | 77±18 | 70±21 | <0.001 |
| NT-proBNP, pg/ml | 242±694 | 204±398 | 198±373 | 218±362 | 346±1206 | <0.001 |
| cTnT, pg/ml | 8.16±7.58 | 7.60±6.77 | 7.67±6.78 | 7.84±7.14 | 9.56±9.2 | <0.001 |
| Interleukin-6, pg/ml | 0.81±0.88 | 0.64 ±0.84 | 0.74 ±0.82 | 0.85 ±0.9 | 1.03 ±0.93 | <0.001 |
| hsCRP, mg/l | 1.35 ±1.48 | 0.96 ±1.36 | 1.20 ±1.35 | 1.43 ±1.41 | 1.82 ±1.64 | <0.001 |
| WBC, ×1000/mm2 | 2.6 ±0.4 | 2.53 ±0.39 | 2.59 ±0.38 | 2.59 ±0.39 | 2.67 ±0.43 | <0.001 |
| LV ejection fraction† | 0.639 | |||||
| ≥55% | 4244 (92.2) | 960 (91.9) | 1076 (92.0) | 1106 (92.8) | 1102 (92.1) | |
| 45–54% | 236 (5.1) | 57 (5.5) | 61 (5.2) | 62 (5.2) | 56 (4.7) | |
| <45% | 123 (2.7) | 28 (2.7) | 32 (2.7) | 24 (2.0) | 39 (3.3) |
*
Continuous variables are presented as mean ± SD.
†
Only available for the original cohort (n=4,603).
BMI = Body mass index; cTnT = Cardiac troponin T; CHD = Coronary heart disease; eGFR = Estimated glomerular filtration rate; HDL = High-density lipoprotein; hsCRP = High-sensitivity C-reactive protein; LDL = Low-density lipoprotein; LV = Left ventricular; NT-proBNP = N-terminal pro-B-type natriuretic peptide. TIA = Transient ischemic attack; WBC = White blood cell count.